This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
by Zacks Equity Research
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
BEAMNegative Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
New Strong Buy Stocks for March 12th
by Zacks Equity Research
AEO, RELY, ADMA, HSY and HTBK have been added to the Zacks Rank #1 (Strong Buy) List on March 12th, 2026.
AEONegative Net Change HSYPositive Net Change ADMANegative Net Change RELYNegative Net Change
biotechs finance
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
by Zacks Equity Research
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
JNJPositive Net Change ANIPNegative Net Change CSTLNegative Net Change
biotechs
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.
RDYNegative Net Change ANIPNegative Net Change
biotechs
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
by Zacks Equity Research
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
BIIBPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
by Zacks Equity Research
MLYS shares rise after the FDA accepts NDA for lorundrostat to treat hypertension. A decision from the regulatory body is due on Dec. 22, 2026.
ANIPNegative Net Change REPLNegative Net Change PHATNegative Net Change MLYSNegative Net Change
biotechs
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
by Ahan Chakraborty
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change HIMSNegative Net Change
biotechnology biotechs medical pharmaceuticals
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
by Zacks Equity Research
Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.
NVSNegative Net Change VRTXPositive Net Change TVTXPositive Net Change
biotechs medical pharmaceuticals
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
by Zacks Equity Research
GSK licenses linerixibat to Alfasigma for cholestatic pruritus in PBC, securing $300M upfront and potential milestone payments as the drug awaits FDA review.
GSKPositive Net Change ANIPNegative Net Change ALXOPositive Net Change
biotechs medical pharmaceuticals
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
by Zacks Equity Research
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
LXRXNegative Net Change ANIPNegative Net Change XENENo Net Change REPLNegative Net Change
biotechs